Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Edgestream Partners L.P.

Edgestream Partners L.P. increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 110,293 shares of the biotechnology company's stock after buying an additional 37,085 shares during the quarter. Edgestream Partners L.P.'s holdings in Exelixis were worth $3,673,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Jackson Creek Investment Advisors LLC purchased a new stake in shares of Exelixis in the fourth quarter valued at about $301,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Exelixis in the 4th quarter valued at approximately $240,000. E Fund Management Co. Ltd. increased its holdings in shares of Exelixis by 5.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,055 shares of the biotechnology company's stock worth $501,000 after buying an additional 844 shares during the last quarter. Candriam S.C.A. raised its position in shares of Exelixis by 12.1% during the 4th quarter. Candriam S.C.A. now owns 614,671 shares of the biotechnology company's stock valued at $20,469,000 after buying an additional 66,552 shares during the period. Finally, Inceptionr LLC acquired a new position in Exelixis in the fourth quarter valued at approximately $814,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wells Fargo & Company cut Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price for the company. in a research note on Monday, February 24th. Citigroup boosted their price objective on shares of Exelixis from $38.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. BMO Capital Markets lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and increased their target price for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. JMP Securities reissued a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Finally, StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.24.

Remove Ads

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of the business's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now owns 356,605 shares of the company's stock, valued at $13,479,669. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by insiders.

Exelixis Price Performance

Shares of EXEL stock traded up $0.27 during trading hours on Wednesday, reaching $37.20. 2,750,774 shares of the stock were exchanged, compared to its average volume of 2,087,863. The business's fifty day moving average is $35.18 and its two-hundred day moving average is $32.29. The firm has a market capitalization of $10.41 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.